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Background: The role of nonanatomic wedge resection in the management of
stage I (T1 NO M0) non-small-cell ung cancer continues to be debated 
against the present gold standard of care--anatomic lobectomy. Methods: 
We analyzed the results of 219 consecutive patients with pathologic stage I
(T1 NO M0) non-small-cell ung cancer who underwent open wedge 
resection (n = 42), video-assisted wedge resection (n = 60), and lobcctomy 
(n = 117) to assess morbidity, recurrence, and survival differences between 
these approaches. Results: There were no differences among the three 
groups with regard to histologic tumor type. Analysis demonstrated the 
wedge resection groups to be significantly older and to have reduced 
pulmonary function despite a higher incidence of treatment for chronic 
obstructive pulmonary disease when compared with patients having lobec- 
tomy. The mean hospital stay was significantly less in the wedge resection 
groups. There were no operative deaths among patients having wedge 
resection; however, a 3% operative mortality occurred among patients 
having lobectomy (p = 0.20). Kaplan-Meier survival curves were nearly 
identical at 1 year (open wedge resection, 94%; video-assisted wedge 
resection, 95%; lobectomy, 91%). At 5 years survival was 58% for patients 
having open wedge resection, 65% for those having video-assisted wedge 
resection, and 70% for those having lobectomy. Log rank testing demon- 
strated significant differences between the survival curves during the 5-year 
period of study (p = 0.02). This difference was a result of a significantly 
greater non-cancer-related death rate by 5 years among patients having 
wedge resection (38% vs 18% for those having lobectomy; p = 0.014). 
Conclusion: Wedge resection, done by open th/oracotomy or video-assisted 
techniques, appears to be a viable "compromise" surgical treatment of 
stage I (T1 NO M0) non-small-cell lung cancer for patients with cardiopul- 
monary physiologic impairment. Because of the increased risk for local 
recurrence, anatomic lobectomy remains the surgical treatment of choice 
for patients with stage I non-small-cell lung cancer who have adequate 
physiologic reserve. (J Thorac Cardiovasc Surg 1997;113:691-700) 
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A natomic lobectomy with mediastinal nodal stag- ing is the present standard of  care for patients 
with stage I or stage II non-small-cell lung cancer. 
The potential role of sublobar resection, nonana- 
tomic wedge resection, or segmentectomy as an 
alternative to lobectomy for the primary manage- 
ment of peripheral stage I lung cancers has been 
investigated by several surgical groups. 1-7 A corn- 
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Fig. 1. Typical peripheral T1 N0 non-small-cell lung can- 
cer, which was the focus in this study of wedge resection 
versus lobectomy. 
mon theme throughout hese investigations i that 
the general survival after wedge resection of stage I
lung cancers has been equivalent o that of lobec- 
tomy but that local recurrence rate has been signif- 
icantly higher. Because of this local recurrence 
problem, these "compromise" resections have been 
primarily directed toward small peripheral esions 
found in patients with impairment in cardiopulmo- 
nary reserve who are not candidates for lobecto- 
my) '  6, 7 
We have previously demonstrated that the vid- 
eo-assisted thoracic surgical (VATS) approach to 
pulmonary wedge resection is associated with less 
patient morbidity and a shorter hospital stay than 
is wedge resection performed through open tho- 
racotomy, s We and others have also suggested 
that the VATS approach may have equivalent 
efficacy to open surgical techniques for the diag- 
nosis and management of a variety of thoracic 
oncologic onditions. 9-11 The efficacy of the VATS 
approach for wedge resection of peripheral ung 
cancers has not been directly addressed. We chose 
to compare our results with the VATS approach 
to nonanatomic wedge resection to open ap- 
proaches for wedge resection and lobectomy in 
the oncologic surgical management of T1 NO 
non-small-cell lung cancers. Specific end points 
related to operative morbidity, local control of the 
malignant process, and overall patient survival 
were the focus of this investigation. 
Patients and methods 
From January 1989 to July 1994 we treated 219 patients 
having pathologically determined peripheral st ge I (T1 
NO) non-small-cell lung cancers with surgical resection 
(Fig. 1). The standard preoperative evaluation centered 
around a careful history and physical examination, full 
pulmonary function analyses with blood gas determina- 
tion. roentgenographic assessment including standard 
posterolateral chest films, and computed tomography of
the chest and upper part of the abdomen. No further 
metastatic workup was performed routinely; however. 
other studies were used selectively to investigate specific 
preoperative symptoms potentially related to metastatic 
disease. 
One hundred seventeen patients underwent anatomic 
lobectomy through a muscle-sparing thoracotomy. Wedge 
resection of the primary cancer was performed as primary 
therapy through a limited lateral muscle-sparing thoracot- 
omy in 42 patients and by using VATS techniques in 60 
patients. The decision to use wedge resection as the 
primary therapy for pe ipheral tung cancer was related to 
the surgeon's impression that significant tmpalrment in 
the patient's physiologic ondition precluded lobectomy 
as a resective option. The age and degree of underlying 
pulmonary disability in these patients with T1 NO lung 
cancer undergoing the various forms of resection (open 
wedge, VATS wedge, and lobectomy) are noted in Table 
L Patients undergoing wedge resection were older and 
had significantly greater preoperative pulmonary dysfunc- 
tion necessitating bronchodilator t eatment than the pa- 
tients undergoing pulmonary lobectomy. 
To accomplish the open pulmonary resections (lobec- 
tomy and wedge resection) in this clinical series, tandard 
axillary, auscultatory triangle, or lateral muscle-sparmg 
thoracotomles were performed with the use of the tech- 
niques previously described by several investigators. 12.13 
The axillary muscle-sparing thoracotomy approach was 
primarily used to approach upper lobe lesions. A lateral 
muscle-sparing thoracotomy or an auscultatory triangle 
muscle-sparing approach was used to approach lower 
lobe, lingular, and middle lobe lesions. 
The actual techniques used for open wedge resection 
and VATS wedge resection in this report have been 
described by us previously.14 With regard to VATS wedge 
resection, three sites of intercostal access were strategi- 
cally positioned to allow for the most opportune manipu- 
lation of instrumentation about the target area. Endo- 
scopic stapling devices (United States Surgical Corp., 
Norwalk. Conn.. or Ethicon Endosurgical Corp., Cincin- 
nati. Ohio l were used to accomplish the wedge resection 
in 90~ of the open and VATS wedge resections in this 
series. The neodymium-yttrium-aluminum-garnet l ser 
c Heraeus Lasersonics Inc.. Milpitas. Calif.. or Laserscope 
Inc.. model 704. KTEYA119995, San Jose. Calif.) was 
used as the primary or ancillary resective tool in approx- 
imately 10% of wedge resections in this series. 
Mediastinal and hilar lymph node staging was routinely 
performed uring the surgical management of all patients 
undergoing resection to ensure that inadvertent inclusion 
of higher stage cancers did not adulterate this analysis. 
Radical mediastinal lymph node dissection was not per- 
formed. During wedge resection procedures (open and 
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Table I. Demographics of age and the percentage of 
patients who had T1 NO disease and underlying 
pulmonary disability undergoing the various 
resections for lung cancer 
Open VATS p 
WR WR vs Lobectomy Value 
Age (yr) 68 71 vs 63 0.0002 
COPD (%) 64 69 vs 14 0.001 
FEV 1 (% predicted) 69 61 vs 88 0.0001 
DLCO (% predicted) 73 51 vs 81 0.001 
WR, Wedge resection; COPD, chronic obstructive pulmonary disease; 
FEVI, forced expiratory volume in 1 second; DLCO, diffusing capacity for 
carbon monoxide. 
VATS), interlobar lymph nodes were examined and bi- 
opsy samples were taken if there was any question of 
enlargement on preoperative roentgenographic assess- 
ment or during intraoperative inspection. 
Postoperative care was similar between lobectomy and 
wedge resection groups but for a few minor exceptions. 
Patients undergoing lobectomy were admitted overnight 
to the surgical intensive care unit for observation, whereas 
most of those having wedge resection were sent to a 
specialized thoracic surgical stepdown unit immediately 
after anesthetic recovery. The vast majority of patients 
undergoing open thoracotomy for wedge resection or 
lobectomy were managed with postoperative pidural 
analgesic measures during the early postoperative p riod. 
Epidural analgesia was rarely used for patients undergo- 
ing VATS wedge resection. Early extubation after reversal 
of anesthesia was routinely used for all patients. All 
untoward postoperative events and the total period of 
postoperative hospitalization were recorded. Complica- 
tions considered as significant in this analysis included 
respiratory failure necessitating ventilatory support, em- 
pyema, wound infection, air leak greater than 7 days, 
myocardial infarction/failure, cardiac arrhythmias, and 
postoperative pneumonia/sepsis. After discharge from the 
hospital, all patients have been followed up by the oper- 
ating surgeon in their respective clinics with physical 
examination and standard posteroanterior chest roentgen- 
ograms at 3- to 4-month intervals for the first 2 years after 
the operation and at 6-month intervals thereafter. Is Com- 
puted tomography was only selectively used as a follow-up 
screening study when the screening roentgenographic 
studies suggested a new abnormality. Patient follow-up 
was complete with regard to survival and documentation 
of recurrence in all patients to within months of this 
analysis. The median length of documented follow-up for 
open wedge resection was 29 months; for VATS wedge 
resection, 24 months; and for lobectomy , 26 months. 
Local recurrence was defined as any recurrence: of the 
primary cancer in the hemithorax after wedge resection or 
any hilar/mediastinal denopathy in the drainage basin 
from the lobe in question. With specific regard to patients 
undergoing lobectomy, local recurrence was defined as 
new disease in the ipsilateral lung parenchyma, bronchial 
stump, or the hilar or mediastinal lymph nodes. Local and 
systemic recurrence was defined as the association of local 
disease and new roentgenographic, nuclear scintigraphic, 
Table II. Wedge resection versus lobectomy for 
stage 1 (T1 NO MO) Lung Cancer 
Open VATS 
WR WR vs Lobectomy p Value 
Operative mor- 0 0 vs 3.3 0.20 
tality (%) 
Postop. stay 7.7 6.3 vs 10.6 0.0002 
(days) 
Local recurrence 24 16 vs 9 0.07 
(%) 
Local/systemic 30 26 vs 19 0.22 
recurrence (%) 
WR, Wedge resection. 
or biopsy evidence of metastatic disease outside the 
ipsilateral hemithorax. Systemic d!sease alone was defined 
as the presence of metastatic disease without recurrence 
within the ipsilateral hemithorax. 
Statistical analysis. All statistical analysis was done 
with SAS Software (SAS Institute, Cary, N.C.) on Macin- 
tosh Power PC computers (Apple Computer, Cupertino, 
Calif.). 
Statistical significance for difference among the three 
treatment groups (i.e., open wedge, VATs wedge, and 
lobectomy) for each continuous variable was evaluated by 
means of a one-way analysis of variance. Significant 
differences in survival times among the three treatment 
groups were calculated from Kaplan-Meier curves with 
the use of the log rank test. 
In addition, to control for the effect of other factors and 
to estimate risk ratios, we used the Cox proportional 
hazard models to examine the effect of treatment on 
survival times. Specifically, the Cox model considered the 
effect on survival time of the following explanatory vari- 
ables: age, tumor size, sex, and treatment type. 
Results 
Analyses of the surgical specimens demonstrated 
that there was no difference in the distribution of 
histologic types of non-small-cell lung cancers be- 
tween the wedge resection and lobectomy treatment 
groups. The median diameter of lesions resected by 
lobectomy was larger (2.0 cm) than that of the 
lesions managed by wedge resection (open wedge, 
1.7 cm; VATS wedge, 1.9 cm); however, these 
differences did not reach statistical significance. 
The primary oncologic end points focused on in 
this study were the relative risks for local recurrence 
and long-term survival after either wedge resection 
or lobectomy for peripheral T1 NO non-small-cell 
lung cancers. The differences in operative mortality 
and length of hospital stay between wedge and 
lobectomy groups were also of interest. These re- 
suits are seen in Table Ii. Local recurrence did 
approach significance in favor of lobectomy and 
operative mortality approached significance favor- 
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Fig. 2. Five-year actual survival differences noted between all patients having wedge resection and all 
those having lobectomy. 
ing patients undergoing wedge resection. There was, 
however, no statistically significant difference in the 
local/systemic recurrence rate between the wedge 
resection groups and the lobectomy group. 
Local recurrence was identified at a median time 
interval of 10 months among patients having wedge 
resection and 19 months among those having lobec- 
tomy. Only three of the 14 patients in whom local 
recurrence occurred after wedge resection were 
considered to be candidates for reresection. The 
remaining patients were not considered for reresec- 
tion because of the severity of their cardiopulmo- 
nary insufficiency, the presence of an associated 
malignant pleural effusion, or significant ipsilateral 
mediastinal adenopathy. Formal segmentectomy 
was performed in two of these patients and comple- 
tion lobectomy in the third patient. Reresection was 
accomplished by completion pneumonectomy in two 
of the six patients having limited hilar recurrences 
after lobectomy. 
Histologic analysis of the resected tumor revealed 
no difference in the degree of microscopic angiolym- 
phatic invasion between patients who had a local 
recurrence and those who have remained free of 
this. Additionally, the "closeness" of the clear sur- 
gical margins, determined semiquantitatively by his- 
tologic examination, did not appear to discriminate 
between patients having local recurrence and those 
not having local recurrence. However, it must be 
remembered that a clear margin, even if it was 
"close," had to have been obtained for inclusion in 
this study. 
We also evaluated the occurrence of significant 
postoperative complications, as defined earlier in 
the Patients and methods section of this article. 
Postoperative complications occurred in 16% of 
patients having VATS wedge resection in contrast to 
28% of patients undergoing open wedge resection 
and 31% of patients undergoing lobectomy (p < 
0.05). 
Although the patient population undergoing 
wedge resection was generally older, with poorer 
pulmonary function, the Kaplan-Meier survival pro- 
portions for all causes appeared nearly identical at 1 
year, and overall survival proportions over the entire 
5-year study period did not differ significantly be- 
tween the wedge resection groups (open wedge/ 
VATS wedge) and the lobectomy group (Fig. 2, log 
rank test, p = 0.056). This was primarily the result of 
an equivalent survival among patients having VATS 
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Fig. 3. Five-year actual survival differences noted between patients having VATS wedge resection and 
those having lobectomy. 
wedge resection and those having lobectomy (Fig. 3, 
log rank test, p = 0.889). Non-cancer-related deaths 
were more common among the patients undergoing 
wedge resection (38% of deaths) than among those 
undergoing lobectomy (18% of deaths) (p = 0.014). 
This non-cancer death proportion occurred more 
commonly in the open wedge resection group, which 
is exemplified in the survival differences noted be- 
tween patients having open wedge resection and 
those having lobectomy (Fig. 4, log rank test, p = 
0.005). 
To control for possible confounding, we created a
Cox proportional hazards model that contained the 
variables tumor size, age, and sex, along with treat- 
ment type (lobectomy, VATS wedge, and open 
wedge resection). Afte r controlling for the effect of 
these other variables, we found a significant associ- 
ation (p = 0.042) for treatment type. Specifically, 
patients undergoing lobectomy had a lower survival 
than those having VATS wedge resection, although 
the difference was not significant (risk ratio = 0.80; 
95% confidence interval 0.49 to 1.24); by contrast, 
the survival in patients having lobectomy was signif- 
icantly greater than that in patients having open 
wedge resection (risk ratio = 1.63; 95% confidence 
interval 1.11 to 2.36). 
Sex and tumor size showed no significant associ- 
ation with survival time. The only other significant 
variable found from the Cox model was age (p = 
0.03; risk ratio = 1.03; 95% confidence interval 
1.002 to 1.066). 
Comment 
The history of the evolution of the surgical treat- 
ment of lung cancer is interesting. As with the 
surgical management of other malignant diseases, 
arguments recorded in the thoracic surgical itera- 
ture regarding the most appropriate xtent of surgi- 
cal resection eeded to properly manage potentially 
curable carcinoma of the lung have been passion- 
ately debated. 7' 9"11'16-2z Earlier in this century, 
pneumonectomy was believed to be the only justi- 
fied choice for resection in the treatment of carci- 
noma of the lung. Equivalent survival with lobec- 
tomy was reported later by physicians aiming to 
reduce the morbidity and mortality associated with 
pulmonary resection for lung cancer. The relative 
efficacy of sublobar pulmonary resections with re- 
spect o patient survival in the treatment of periph- 
eral lung cancers has also been noted. This has 
particularly been the case for patients who are 
marginal candidates for any thoracic surgical inter- 
vention because of impaired cardiopulmonary func- 
tion, advanced age, or other significan t comorbid 
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Fig. 4. Five-year actual survival differences noted between patients having open wedge resection and those 
having lobectomy. 
diseases. Indeed, a number of investigations have 
been reported that document the equivalent survival 
efficacy of open wedge resection and lobectomy for 
the management of peripheral T1 NO non-small-cell 
lung cancers. 1-7 The results of this investigation 
reaffirm this relative fficacy of wedge resection for 
small peripheral T1 NO lung cancers and also for the 
first time document the relative utility of the VATS 
approach as a means of accomplishing wedge resec- 
tion for selected patients with these lesions. It is 
important to reiterate that the T1 NO lesions ap- 
proached in this investigation were all peripheral 
and had no bronchoscopic evidence of endobron- 
chial extension. The intraoperative management 
was also equivalent with regard to intraoperative 
lymph node staging and assurance that the margins 
of resection were negative for tumor involvement. 
The minimum criteria for wedge resection of pe- 
riphera ! lung carcinomas were as follows: 
• Less than 3 cm in diameter (T1 lesion) 
• Location in the outer third of the lung and 
technically approachable bywedge resection (sta- 
pled, electrocautery, or laser) 
• Absence of endobronchail extension 
• Clear margins of resection according to frozen 
section 
• Intraoperative mediastinal nd hilar nodal staging 
As has been demonstrated before, 2 this investiga- 
tion also showed that local recurrence of the malig- 
nant process after sublobar resection isgreater than 
that seen after lobectomy. 7 However, the develop- 
ment of local recurrence after a "clear" resection 
may more accurately represent a regional manifes- 
tation of an aggressive, metastatic phenotype of the 
malignant tumor, rather than an important failure of 
our surgical therapy leading to subsequent meta- 
static diseaseY -27 
The clinical significance of the locally recurrent 
process has been hard to determine among the 
physiologically impaired patients for whom wedge 
resection was chosen in this investigation. To our 
understanding, death can be attributed to the local 
recurrence only if the patient dies of massive he- 
moptysis, sepsis from an obstructing pneumonia or 
empyema, or local invasion into mediastinal struc- 
tures by the recurrent umor leading to massive 
hemorrhage or cardiac failure. Pulmonary func- 
tional difficulty related to diffuse lymphangitic 
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spread about a local recurrence may also signifi- 
cantly contribute to the patient's death, but this local 
process is almost always associated with widespread 
systemic metastases. The most common occurrence 
we have witnessed is to have the patient die with 
local recurrence, but it is rare in our experience to 
have patients die of the locally recurrent process. 
The results of this investigation and those con- 
ducted previously should bring us to realize that the 
primary determinant of long-term survival after 
"total" surgical excision of T1 NO lung cancers 
relates to the biology of the malignant process, a8 
Benfield's comments 29 on the 1990 manuscript by 
Read, Yoder, and Schaeffer s probably relate this 
message best, although his remarks were specifically 
related to the relevance of lymph node involvement 
by the malignant process. He stated, "...I believe 
there is ample evidence that lymph node metastasis 
in cancer is evidence of systemic disease. We tho- 
racic surgeons need to keep up with this modern 
oncologic concept, test we continue to focus on 
lymph node excision as an effective means of cancer 
control. As in breast cancer, melanoma, colon can- 
cer, and other cancers, lymph node excision is 
largely of prognostic value--useful for identifying 
patients who need systemic therapy." Similarly, we 
might question the importance of total lobectomy 
for the management of small peripheral T1 NO lung 
cancers that can be clearly removed by a generous 
wedge resection. 
Because of the increased risk of local recurrence, 
at this time we continue to use lobectomy as our 
primary means of resection of peripheral T1 NO lung 
cancers identified in good-risk patients. Although 
the postoperative morbidity and mortality with lobar 
resection is relatively small, 3° these negative postop- 
erative consequences may be more important than 
the development of a local recurrence that may 
primarily be the harbinger of an aggressive malig- 
nant phenotype. Certainly for the patient with phys- 
iologic impairment, wedge resection accomplished 
by open thoracotomy or VATS appears to be a valid 
management alternative to lobectomy for appropri- 
ately selected peripheral T1 NO lung cancers. 
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Discussion 
Dr. James B. Mark (Stanford, Calif.). Dr. Landreneau 
and his coauthors have tried to answer another important 
question--whether wedge resection, thoracoscopic or 
open, is as good as lobectomy in the treatment of stage I
lung cancer. They have amassed 219 patients from five 
institutions over a 51/2-year period, or eight patients per 
institution per year, so those of us who do relatively few 
such operations do not have to feel too far behind. 
Pooling patients and data has certain advantages. What 
the authors tell us is that even though the rate of local 
recurrence is greater with wedge resection than with 
lobectomy, the actuarial survival is insignificantly different 
in the two groups at 4 years. Presuming that local recur- 
rence means that cure is not possible, these figures must 
mean that if there is no local recurrence there is a greater 
chance of a systemic recurrence or that lobectomy itself 
causes more systemic recurrences. I have a hard time 
sorting all that out. 
In Table II of the article there are some things that to 
my mind are counterintuitive. The operative mortality of 
0% for the wedge resections versus 3.3% for the lobecto- 
mies is not significant except to the four patients who died. 
The 30% to 50% difference in postoperative stay between 
the wedge resection and lobectomy groups, however, is 
highly significant. There is a 40% difference in local/ 
systemic recurrence (not significant) and an insignificant 
difference in local recurrences (between 5% in lobecto- 
mies and 15% or 17% in wedge resections). Dr. Grunk- 
emeier is now a member of our organization, and I hope 
he is present and can explain this, because I really do not 
understand the statistics. I do not doubt them; I just do 
not understand them. 
I have a few technical questions. The first involves 
intraoperative lymph node staging. I know that I can do a 
better job of lymph node dissection in the paratracheal 
and subcarinal regions with the chest wide open than I can 
thoracoscopically or through a limited incision. I would 
like to hear a little more about he technique and extent of 
lymph node sampling or dissection used by the authors 
when they do VATS or open wedge resection or even 
lobectomy. 
Dr, Landreneau. Regarding the statistical analysis, Dr. 
Mark. the local recurrence rate was 0.07. which ap- 
proached significance. These numbers were affected by 
the relatively small sample sizes ilwolved with recurrences 
in all groups. The local/systemic resistance was also insig- 
nificant (p - 0.22). 
Dr. Mark. But that is a 40% difference between 23% 
and 24% on the one hand and 17% on the other hand. 
There is a 40% difference in recurrence rates between the 
wedge resections and the lobectomies. 
Dr, Landreneau. With regard to nodal staging and 
sampling, stations from levels 4 and 7 were routinely 
evaluated and also sampled in both the VATS and open 
wedge resection groups. The hilum was explored, and if 
no obvious disease was palpated a biopsy was not under- 
taken. 
Our philosophy was similar with regard to open resec- 
tion. We did not routinely sample hilar nodes with the 
lobectomy specimens. They were looked at. The hilar 
nodes that were removed were part of the tissue within the 
block of resection that was associated with the lobectomy. 
Again, biopsy samples of stations 4 and 7 were routinely 
taken in all circumstances. I would assume that there is 
some stage II disease in our wedge resection group or 
stage III disease that may have been occult, yet the 
survival was similar. Understanding this. the survival 
pattern seen here may be more reflective of the biology of 
the disease rather than the importance of an aggressive 
nodal resection. 
Dr. Mark. What you are saying is that, like Dr. Benfield. 
you believe that if there is lymph node extension it is not 
really worth resecting those lymph nodes. In other words, 
sample them to find out if there is "systemic disease," but 
do not include lymph node dissection as part of either 
wedge resection or lobectomy. 
Dr. Landrenean. I think that is the consensus of our 
group. 
Dr. Mark. There is a small difference in opinion. 
Second question: What is the definition of adequate 
sublobar esection? You mention clear surgical margins. 
How clear is clear? Are frozen sections done on all 
resected specimens and all nodes? How wide a margin do 
you consider adequate around a T1 or even T2 tumor? 
Dr. Landreneau. The latter part of your question is 
indeterminate as far as 5 ram. 1 cm, or whatever as being 
adequate. Frozen section analysis was performed, and the 
results were confirmed by the final pathologic assessment 
for permanent section analysis that the margins were clear 
in these circumstances. Obviously, if the local recurrence 
rate is increased, some cells are being left in transit within 
the lymphatics. What does that mean for the patient's 
prognosis? The biggest issue, in my mind, is determining 
the importance of local recurrence as it affects patient 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 113, Number 4 
Landreneau et al. 6 9 9 
survival. Is it a primarily important variable or simply a 
harbinger of a virulent malignant process? 
Dr. Mark. The third and last question: In patients who 
are going to have a wedge resection, how do you decide 
whether to use the thoracoscopic or open technique? 
Dr. Landreneau. Our bias is to perform wedge resec- 
tions thoracoscopically for peripheral small lesions. 
Deeper lesions would not have been included in this 
study. A peripheral lesion can be safely encompassed 
without violation of the visceral or deep margins of the 
resection. 
Dr. Mark. You did as many open wedge resections as 
you did thoracoscopic wedge resections in this group. Why 
did you do any open wedge resections for peripheral 
lesions that could have been removed thoracoscopically? 
Dr. Landreneau. In general, open wedge resection was 
done earlier in each surgeon's reported experience here. 
Some of us moved to the VATS approach earlier than 
others, leading to some overlap in the VATS and open 
wedge approach. The lesion characteristics for inclusion 
(peripheral T.1 lesions) into this analysis were universally 
applied. At this time, most all of these lesions are ap- 
proached with VATS when wedge is being considered. 
Dr. Mark. You have done very well with this analysis as 
far as you go, and I believe you add to our comfort level 
when we do wedge resections of peripheral lung cancers in 
poor-risk patients, as suggested by Jensik and others some 
years ago. I am not yet prepared to do wedge resections in 
good-risk patients, nor apparently are you. The adjuvant 
therapy is not as good as we would like it to be, certainly 
not as good as it is in breast cancer. I am not even sure 
that open wedge resection is safer than lobectomy in some 
poor-risk patients. In fact, you performed a second oper- 
ation in a few of your poor-risk patients who had local 
recurrence after wedge resection, and in one of those 
patients the operation was a lobectomy. I continue to do 
wedge resections thoracoscopieally if technically feasible 
in poor-risk patients. At the moment only clinical judg- 
ment separates the good-risk from the poor-risk category. 
There is still a place for a properly controlled and 
randomized study to definitively answer the questions. 
Dr. Robin Cohen (Los Angeles, Calif.). When we started 
using VATS for wedge resections for cancer, we noticed not 
only that were we getting local recurrences but also that they 
seemed to come early, many of them in less than a year. We 
attributed this to technical factors. Can you comment on 
that? Also, what do you tell the patients knowing that they 
have a significant chance of local recurrence after wedge 
resection? What kind of time course do you expect? Were 
there any differences in time between the open wedge 
resections and the VATS wedge resections? 
Dr. Landreneau. In the wedge resection group the 
median time of recurrence was around 11 months. In the 
lobectomy group recurrence was recognized at about 19 
months. The difference between the groups was signifi- 
cant. We had the impression that we might have un- 
leashed some local factors, such as trauma, that provided 
a milieu in which the residual tumor could grow. That is 
speculation. However, because of the nature of the resec- 
tion, there is parenchyma round the area that was 
removed that allowed us to identify the disease earlier 
than following lobectomy where appreciation of local 
recurrence can be delayed until new hilar prominence on 
bronchial stump recurrence is noted. There was no differ- 
ence in local recurrence between the open wedge resec- 
tion group and the VATS group. 
To answer another of your questions, these patients 
generally had more physiologic impairment, and they 
knew that we were doing a sublobar esection because of 
their physiologic impairment. They were informed of the 
increased risk for local with the wedge resection approach. 
Lobectomy continues to be our standard of care for 
good-risk patients with T1 lesions, although I have some 
question as to whether lobectomy is necessary for the 
management of the 1 cm very peripheral lesion. 
Dr. John R. Benfield (Sacramento, Calif.). I have just 
reviewed the Lung Cancer Study Group manuscript, 
which will be appearing in the Annals of Thoracic Surgery. 
My recollection is that there is not a true survival differ- 
ence and that it is arguable as to whether there is a true 
survival difference. The main argument is the local recur- 
rence issue. In this era of outcomes research, it would be 
extraordinarily important for us to know what a local 
recurrence really meant to the patients. Did they have 
reoperations? Did those local recurrences really contrib- 
ute to their death? Did those local recurrences interfere 
with their quality of life? Would it have been worth doing 
a large operation to avoid a possible local recurrence in 
those patients? Those are the questions that have to be 
answered, in addition to the hard statistic of whether or 
not a local recurrence occurs. 
Dr. Landreneau. I agree with you wholeheartedly. In 
most patients in this group (60% of the 17 patients who 
had a recurrence) the recurrence caused no symptom- 
atic problem, and it was later identified that these 
patients died of systemic disease. The problem in the 
other 30% or so of the patients was chest wall pain. 
Although compromised, we felt reresection was indi- 
cated. Thus there were only three of 17 patients whom 
we thought we could potentially help with reresection. 
We did not think a second resection useful in the others 
because of their impaired physiology. Our definition of 
local recurrence was any disease recurrence within the 
ipsilateral hemithorax, a very broad definition. 
Dr. Benfield. You stated that your margins of resection 
were clear in all cases. Were there instances in which the 
margins were so close that you reresected additional 
tissues to be sure that you had a free margin or in which 
a reresection at the time of the initial operation was 
required to achieve a free margin? 
Dr. Landreneau. It was a patient selection issue. There 
were circumstances in which, after firing the endoscopic 
stapler during a VATS wedge, we realized that the base 
of the margin would be compromised. Conversion to an 
open wedge approach followed. Better control of the 
lung parenchyma beneath the lesion was obtained for 
the stapler and on laser resection. A subset of these 
patients were treated with laser resection before the 
endoscopic stapling devices became readily available, 
and several of the specimens were said to have close 
margins. I looked at the close margins versus distant 
margins and saw no difference in the incidence of local 
recurrence. Histologic findings of lymphangitic spread 
within the specimen also had no effect on local recur- 
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rence. Those are the things I was hoping to find as 
identifiers of local recurrence, but I could find nothing 
in the limited analysis we had. 
Dr. Arthur N. Thomas (San Francisco, Calif.). I have 
found that it is much more difficult to do a thoracoscopic 
wedge biopsy if the lesion is at all deep in the lung. In fact, 
in some of the wedge excisions the true margin is really 
not the width of the wedge. Rather, the lesion is subsero- 
sal and you are really looking at a couple high-power fields 
between the tumor and the surface of the lesion. Is your 
decision to do an open or a VATS technique influenced 
by that sort of factor and might that be related to the 
recurrences in the patients undergoing VATS tech- 
niques? 
Dr. Landreneau. If there was any possibility, based on 
visceral pleural involvement, that the lesion was a T2 
lesion, the patient was excluded from this analysis, and 
the stage of disease was determined by the final patho- 
logic evaluation. We were dealing with lesions that were 
technically feasible for VATS resection. The clinical 
judgment issue that Dr. Mark brought up is paramount 
in deciding whom you can and cannot treat in this 
fashion. Patients with deeper lesions were not treated 
by wedge resection and were also excluded from the 
lobectomy group in this analysis. We were dealing with 
small T1 lesions, with a mean size of less than 2 cm, that 
were anatomically feasible for wedge resection in these 
circumstances. 
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